PEB - Pacific Edge Ltd

[MAC]

Ticks all the boxes very well, good period growth, sufficient cash on hand, goal confirmation, tracking to plan, positive outlook.

There’s been an awful lot achieved in the last 12 months to be seen when all laid out like that, plenty more to come for the year ahead too it would seem and accelerating also.

All on track against the commercialisation plan and five year goal, perhaps the SP will start to reflect that again now.

Well done to all the hard working folk at Pacific Edge, NZ and US, you deserve a pat on the back.

[Casino]

• Signed agreements with National Provider Networks – Multiplan, FedMed, ACPN, Stratos
• Kaiser Permanente signed to a User Program for 2015 completion
• User programmes in place with with a growing number of Large Urology Group practices
• Commercial sales achieved and revenue growing in the US
• US sales executive team expanded from four to twelve through August and September this
year
US focus for FY15
 Increase the number of User Programmes
 Continue to translate existing user programmes into paying commercial relationships
 Grow the total sales of Cxbladder

• Successfully completed two validation studies with Waitemata and Canterbury District
health boards with results supporting clinical study findings
• Signed agreements with Urologists servicing BOP and Lakes District Health Boards
• Continuing to work with National Health Council to put Cxbladder into the Standard of Care
in NZ
• Launched the e-commerce platform for Urologists and patients in NZ
• Commercial sales achieved and revenue growing in the New Zealand market
• Commercial sales from Healthscope, our licensed partner in Australia, are slow
• Commercial partnership in Spain expected to start soon

Objectives
• Focusing on American healthcare market
• Roll-out of Cxbladder Triage
• Evaluating the roll-out to Sout East Asian markets in Singapore, Taiwan and Thailand
• Developing new bladder cancer diagnostic tests
• Aiding the launch of Cxbladder triage in New Zealand as a precursor for the US
• Targeting gross revenues of over $NZ100m after five full years of trading
• Continuing to rollout our User Programmes to targeted clinical groups and urologists in the
US, New Zealand and Australia


What about CMS coverage? Where are we with this?

[winner69]

US Lab Sales $460k
NZ Lab sales $70k
Research Nz / Australia $480k

Methinks actual test sales $550k in US and NZ

[klid]

Well I am first on those orders at $0.90. I set the price it looks?

[crayfish]

370k total receipts from customer.......... what a joke.
No talk of CMS.
Stated outlook absolute rhetoric with no numbers.
Happy for everyone else to be buying.

[crayfish]

US Lab Sales $460k
NZ Lab sales $70k
Research Nz / Australia $480k

Methinks actual test sales $550k in US and NZ

I think thats spot on winner, you have done well to see through the smoke and mirrors.

[AndyLP]

Really solid result.

CXBladder Triage too -
New Product: Cxbladder Triage launches on time and to plan in December 2014.

Well, cool. "launches" past tense.. December 2014 hasn't arrived yet.?

[klid]

Really solid result.

CXBladder Triage too -
New Product: Cxbladder Triage launches on time and to plan in December 2014.

Well, cool. "launches" past tense.. December 2014 hasn't arrived yet.?

Halt, correction. Jokes.

Who's this fella stacking up $1? Stop it. Going to have a shower, back at 9:59.

[twotic]

First of all congrats on what on the surface appears to me to be a good results.

Can I ask though, am I missing something on the graph on pg 3 of the presentation (Lab throughput)? I can't see any numbers (only % change)?? Seems ridiculous...am I missing something?

[winner69]

$1m of test revenue, up 1,000%. That's probably between 1,000 and 1,500 PAID tests.

This is excellent progress.

I sure that revenue line includes grants and other services (in this part of the world)

Segment numbers suggest $550k in tests